- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00319826
Virulence Determinants in S Aureus Bacteremia
April 26, 2016 updated by: Duke University
Virulence Determinants in Staphylococcus Aureus Bacteremia
The purpose of this study is to investigate why some people develop life-threatening infections caused by the bacteria Staphylococcus aureus, while other people do not.
It is possible that the infectious ability of the bacteria can determine whether an infection develops and its severity.
The investigators will look at old blood and nasal specimens collected from 1000 adults who had S. aureus infections and who were hospitalized at Duke University Medical Center.
Previously collected health information regarding these patients and the specific bacterial traits in the samples will be studied.
Eventually this information may be used to help treat and prevent S. aureus infection.
Study Overview
Detailed Description
The purpose of this study is to more thoroughly investigate the impact of bacterial genetic characteristics on the outcome of patients with S. aureus bacteremia (SAB).
The investigators will address salient aspects of bacterial virulence using strong collaborative relationships with authorities in bacterial genetics and genomics.
The overall hypothesis of this investigation is that distinct bacterial virulence determinants influence the severity of S. aureus infection.
The specific hypothesis is that virulence determinants associated with clinical outcome of S. aureus infection segregate into clonal groups, identified by Multilocus Sequence Typing (MLST), and can be localized in the genome by comparative genetic hybridization (CGH).
The investigators have established the following aims to pursue this hypothesis.
Specific Aim 1: Define the allelic diversity of S. aureus bloodstream isolates using MSLT.
Allelic profiles among the 1000 isolates will be compared using the program BURST (Based Upon Related Sequence Type), and relatedness of lineages in the overall collection will be defined.
Specific Aim 2: Define the genomic diversity of S. aureus bloodstream isolates using CGH.
Using MLST results, a subset of 200 isolates will be selected to undergo further study.
These ~200 isolates will form a unique collection hereafter referred to as the SAGA (S. aureus genomic analysis) collection.
The genomic diversity of the SAGA subset will be defined using CGH.
Specific Aim 3: Correlate MLST and CGH results, MLST and clinical outcome, and CGH, and clinical outcome, and make SAGA isolates available to the scientific community.
In this Specific Aim, the discriminate ability of MLST and CGH will be compared among the SAGA subset isolates undergoing both assays.
The association between bacterial clonality and clinical outcome will be considered among 1000 S. aureus isolates collected from adults at Duke University Medical Center who had S. aureus infections undergoing MLST.
The association between clinical outcome and the presence or absence of virulence factors and pathogenicity islands in the S. aureus genome will also be considered among the 200 SAGA subset isolates undergoing CGH.
The products of this study will include an increased understanding of genetic diversity in S. aureus and the role of this genetic diversity on determining the severity of infections caused by S. aureus.
The full value of the current proposal also includes the potential future benefit to the research community as a whole if associations between pathogen genotype and clinical outcome, only possible to identify using such a large and clinically well-characterized collection of isolates, can be defined.
To amplify these potential downstream dividends, the final goal of Specific Aim 3 will be to make SAGA subset isolates, corresponding MLST types, and CGH profiles available to the scientific community through the repository maintained by the Network for Antimicrobial Resistance in S. aureus (NARSA).
The long-term objectives of this project are to: (1) identify bacterial genes contributing to the severity of infection in isolates from a large cohort of patients with SAB; and (2) ultimately use these genes to identify novel interventions for the control of S. aureus pathogenesis by investigating genes that govern the virulence of this emerging pathogen.
Culture-confirmed SAB nasal carriage isolates and/or bloodstream bacterial isolates previously collected from 1000 inpatient adults at Duke University Medical Center will be used in this study.
Study Type
Observational
Enrollment (Actual)
1354
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Bacterial strains are used from patients with particular syndromes (e.g.
nasal carraige, endocarditis, osteomylitis) that were be identified using the Bloodstream Infections Registry.
No new subjects was or will be enrolled within the current investigation.
Description
Inclusion Criteria:
- Adults (>= 18 years) with culture-confirmed Staphylococcus aureus bacteremia (SAB). Patients with SAB transferred to Duke University Medical Center are eligible if speculation and antibiotic susceptibilities are confirmed by the Duke Clinical Microbiology Laboratory.
- Absolute neutrophil count of > 1000 cells/cubic millimeter at the time that the initial positive blood culture is obtained.
- Patient or patient's representative provides signed informed consent allowing study participation.
Exclusion Criteria:
- Prior enrollment of patient in this investigation (to ensure statistical independence of observations).
- Staphylococcus aureus bacteremia (SAB) that is not confirmed by culture and speciation at the Duke Clinical Microbiology Laboratory.
- Outpatient status.
- Isolation of any pathogen other than S. aureus from bloodstream.
- Inability of patient or patient's representative to provide written informed consent.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
1
Subjects with Staphylococcus Bacteremia
|
|
2
Healthy (Non-infected) Control Subjects in the Nasal Carriage Group
|
This is an observational study with no intervention
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cure vs. recurrence of Staph infection vs. death
Time Frame: 12 weeks
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Vance G. Fowler, MD, Duke UMC
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2004
Primary Completion (Actual)
August 1, 2013
Study Completion (Actual)
August 1, 2013
Study Registration Dates
First Submitted
April 27, 2006
First Submitted That Met QC Criteria
April 27, 2006
First Posted (Estimate)
April 27, 2006
Study Record Updates
Last Update Posted (Estimate)
April 28, 2016
Last Update Submitted That Met QC Criteria
April 26, 2016
Last Verified
April 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00014073
- 04-087
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bacteremia
-
Armata Pharmaceuticals, Inc.United States Department of DefenseRecruitingBacteremia | Staphylococcus Aureus | Staphylococcus Aureus Bacteremia | Bacteremia Due to Staphylococcus Aureus | Bacteremia StaphUnited States, Australia
-
Osijek University HospitalCompletedSepsis | Gram-negative Bacteremia | Gram-Positive BacteremiaCroatia
-
Rabin Medical CenterCompletedGram Negative BacteremiaIsrael, Italy
-
Duke UniversityMerck Sharp & Dohme LLCCompletedBacteremia | Gram-negative BacteremiaUnited States
-
The First Affiliated Hospital of Xinxiang Medical...RecruitingSalmonella BacteremiaChina
-
Fundación Pública Andaluza para la gestión de la...Spanish Clinical Research Network - SCReN; Spanish Network for Research in...RecruitingEnterococcal BacteremiaSpain
-
LegoChem Biosciences, IncRecruitingMRSA BacteremiaKorea, Republic of
-
The University of Texas Health Science Center,...RecruitingEnterococcal BacteremiaUnited States, Germany, Spain, Argentina, Chile
-
Aimee LiCompleted
-
Singapore General HospitalSingapore Clinical Research InstituteTerminatedBacteremia Due to Staphylococcus AureusSingapore
Clinical Trials on No intervention
-
Wave NeuroscienceCompletedAutistic DisorderUnited States
-
University of Alabama at BirminghamCompletedInflammatory Bowel Diseases | Colorectal Cancer | Diverticular Diseases | Social BehaviorUnited States
-
Janssen Research & Development, LLCCompletedLupus Erythematosus, Systemic | Lupus Erythematosus, Cutaneous | Lupus Erythematosus, DiscoidUnited States, Poland
-
Hospital Universitario La Paz3MVX CCB and Agaplesion Markus Krankenhaus, Frankfurt a.M., Germany.; Department...RecruitingEmbolism | Atrial Fibrillation | Arrhythmia | Stroke, Acute | Stroke Sequelae | AblationSpain
-
Southern California College of Optometry at Marshall...Ohio State University; University of Houston; Alcon Research; University of Waterloo and other collaboratorsCompletedContact Lens Complication | Contact Lens Acute Red Eye | Contact Lens Related Corneal Infiltrate (Disorder) | Contact Lens-Induced Corneal Fluorescein StainingUnited States, Canada
-
University of Dublin, Trinity CollegeCompleted
-
Hôpital Necker-Enfants MaladesUnknown
-
China Medical University HospitalUnknownIntention to Stay, Turnover Behavior
-
University of PittsburghCompletedChronic Low Back PainUnited States